Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

[1]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[2]  R. Suresh,et al.  Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. , 2003, The American journal of cardiology.

[3]  R. Suresh,et al.  Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[4]  C. Ballantyne,et al.  Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia , 2002 .

[5]  Miettinen Ta.  Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. , 2001 .

[6]  T. Miettinen.  CHOLESTEROL ABSORPTION INHIBITION: A STRATEGY FOR CHOLESTEROL‐LOWERING THERAPY , 2001, International journal of clinical practice.

[7]  D. Federman,et al.  Fatal rhabdomyolysis caused by lipid-lowering therapy. , 2001, Southern medical journal.

[8]  R. Suresh,et al.  Effect of ezetimibe on serum concentrations of lipid-soluble vitamins , 2001 .

[9]  P. Neuvonen,et al.  Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.

[10]  K. Tolman,et al.  Defining patient risks from expanded preventive therapies. , 2000, The American journal of cardiology.

[11]  C. Farley,et al.  Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 , 2000, British journal of pharmacology.

[12]  H. Bays,et al.  Drug Interactions of Lipid-Altering Drugs , 1998, Drug safety.

[13]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[14]  A. Gotto,et al.  Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. , 1998, The American journal of cardiology.

[15]  H. Davis,et al.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. , 1997, The Journal of pharmacology and experimental therapeutics.

[16]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[17]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[18]  H. M. Marvin.  Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. , 1964 .

[19]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[20]  C. Knoop,et al.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[21]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.